An advisory panel to US health regulators voted that AstraZeneca’s diabetes drug Onglyza should include new safety information about the risk of heart failure. An advisory panel to the US Food and Drug Administration (FDA) met Tuesday to review data from a large scale cardiovascular (CV) outcomes trial that assessed …